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Abstract
TOLL-LIKE RECEPTOR 9 AND INTFERON-GAMMA RECEPTOR SIGNALING SUPPRESS THE B CELL FATE
OF UNCOMMITTED PROGENITORS IN MICE
Sheena Baratono
Edward M. Behrens
Hyperinflammatory syndromes come in a variety of flavors with different immunogens and cytokines
leading to variations in organ pathology. This inflammation can be driven by viral, autoimmune, or
neoplastic conditions leading to profound and widespread organ pathology including hepatitis, fever,
splenomegaly, cytokinemia and pan-cytopenias, including T and B lymphopenias. The developing immune
cells in the bone marrow are known to express a variety of cytokine and inflammatory receptors yet the
effects of signaling through these receptors on hematopoiesis is incomplete. Since many infectious and
autoimmune syndromes result in sustained TLR9 stimulation, understanding the effects of TLR9 driven
inflammation on hematopoiesis is important for both questions of pathogenesis as well as possible
therapeutic interventions that might help to restore homeostasis. Utilizing in vitro and in vivo techniques,
we demonstrate that B lymphopoiesis is inhibited during TLR9 driven inflammation from the Ly-6D+ CLP
stage onwards with different effects inhibiting development at multiple stages across B cell development.
We show that TLR9 signaling directly decreases in vitro B cell yields from CLPs, Pro and Pre B cells yet
increases T cell yields. While TLR9 can inhibit B cell growth in vitro, using mixed bone marrow chimeras,
we show in vivo that this TLR9 intrinsic effect is masked, likely due to other TLR9 induced inflammatory
factors that also mediate decreases in B lymphopoiesis. This led us to demonstrate that IFN-γ also
directly inhibits B cell differentiation in vitro as well as when induced by TLR9 in vivo. Microarray and RTPCR analysis of Ly-6D- CLPs points to HOXa9 as an early B-cell directing transcription factor that is
altered by TLR9 induced inflammation, as it and many of its known targets are decreased in Ly-6D- CLPs.
Additionally EBF-1, another factor essential for initiation of the B cell program was transcriptionally
decreased in Ly-6D- and Ly-6D+ CLPs. Our work demonstrates both cellular and molecular targets that
lead to altered B-lymphopoiesis in sustained TLR9 driven inflammation that may be relevant in a number
of infectious and autoimmune/inflammatory settings.
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ABSTRACT

TOLL-LIKE RECEPTOR 9 AND INTFERON-GAMMA RECEPTOR SIGNALING
SUPPRESS THE B CELL FATE OF UNCOMMITTED PROGENITORS IN MICE
Sheena Baratono
Edward M. Behrens

Hyperinflammatory syndromes come in a variety of flavors with different
immunogens and cytokines leading to variations in organ pathology. This inflammation
can be driven by viral, autoimmune, or neoplastic conditions leading to profound and
widespread organ pathology including hepatitis, fever, splenomegaly, cytokinemia and
pan-cytopenias, including T and B lymphopenias. The developing immune cells in the
bone marrow are known to express a variety of cytokine and inflammatory receptors yet
the effects of signaling through these receptors on hematopoiesis is incomplete. Since
many infectious and autoimmune syndromes result in sustained TLR9 stimulation,
understanding the effects of TLR9 driven inflammation on hematopoiesis is important for
both questions of pathogenesis as well as possible therapeutic interventions that might
help to restore homeostasis. Utilizing in vitro and in vivo techniques, we demonstrate that
B lymphopoiesis is inhibited during TLR9 driven inflammation from the Ly-6D+ CLP
stage onwards with different effects inhibiting development at multiple stages across B
cell development. We show that TLR9 signaling directly decreases in vitro B cell yields
from CLPs, Pro and Pre B cells yet increases T cell yields. While TLR9 can inhibit B cell
growth in vitro, using mixed bone marrow chimeras, we show in vivo that this TLR9
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intrinsic effect is masked, likely due to other TLR9 induced inflammatory factors that
also mediate decreases in B lymphopoiesis. This led us to demonstrate that IFN-γ also
directly inhibits B cell differentiation in vitro as well as when induced by TLR9 in vivo.
Microarray and RT-PCR analysis of Ly-6D- CLPs points to HOXa9 as an early B-cell
directing transcription factor that is altered by TLR9 induced inflammation, as it and
many of its known targets are decreased in Ly-6D- CLPs. Additionally EBF-1, another
factor essential for initiation of the B cell program was transcriptionally decreased in Ly6D- and Ly-6D+ CLPs. Our work demonstrates both cellular and molecular targets that
lead to altered B-lymphopoiesis in sustained TLR9 driven inflammation that may be
relevant in a number of infectious and autoimmune/inflammatory settings.
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Chapter 1
Introduction

Systemic hyperinflammation comes in a variety of flavors with different
immunogens and cytokines leading to variations in organ pathology. This inflammation
can be initiated by infectious, genetic, traumatic, autoimmune or neoplastic conditions,
all leading to profound and widespread organ damage. This pathology includes hepatitis,
fever, splenomegaly, cytokinemia and pan-cytopenias, specifically T and B lymphopenias
and in severe cases, hemodynamic insufficiency and death. (Behrens et al., 2011; Canna
et al., 2013; Hinze et al., 2010; Zhang et al., 2014a) The widespread inflammation affects
a variety of organ systems including the bone marrow, which is the site of hematopoiesis.
While bone marrow hematopoietic progenitors express several cytokine and
inflammatory receptors, our knowledge regarding the effects of signaling through these
receptors on hematopoiesis is incomplete. Phenotypic variations in the inflammation
depend on the inciting pathogenic factors and the cytokine networks they induce. One
common thread across various causes of inflammation is that lymphopoiesis is
diminished in the bone marrow, specifically leading to drastic reductions in B and T
lymphopoiesis.

Diseases of hyperinflammation
Bacterial mediated sepsis induces profound inflammation through stimulation of
Toll-Like Receptors (TLR), primarily TLR4, which recognizes the microbial
1

lipopolysaccharide moiety. Stimulation of TLR4 on myeloid cells releases high levels of
tumor necrosis factor α (TNFα) and interleukin (IL) -1 leading to widespread
inflammation and hemodynamic instability.(Beutler and Poltorak, 2001) In mice, chronic
low dose lipopolysaccharide stimulation through TLR4 and the resulting cytokine release
inhibit hematopoietic stem cell quiescence inducing them to differentiate. (Esplin et al.,
2011) Serial bone marrow transplants of stem cells from inflamed mice show that the
inflammation skews stem cells away from the lymphoid lineages. (Esplin et al., 2011;
Nagai et al., 2006) In this model, myelopoiesis in the bone marrow was also decreased
while B cell numbers in the spleen were increased suggesting that inflammation alters
multiple hematopoietic lineages.
Superantigens produce sudden and profound inflammation by non-specific
activation of T cells caused by cross-linking T cell receptors or their ligands, the major
histocompatibility complex. This non-discriminate activation leads to T cell release of
interferon-γ (IFN-γ), which activates macrophages to produce IL-1, IL-6 and TNFα.
(Edwards et al., 1996) These cytokines lead to fever, splenomegaly and shock or
hemodynamic instability. In studies using human and canine cells, antibodies that crosslink the major histocompatibility complex molecule HLA-DR mimicking superantigens
severely diminish hematopoiesis, in part due to increased apoptosis and decreased levels
of stem cell factor. (Hong et al., 1995; Lee et al., 1997; Yamaguchi et al., 1999) In these
mice lymphoid progenitors were decreased in the bone marrow but increased in the
blood, while myeloid progenitors were increased in the bone marrow. This suggests that
inflammation may drive hematopoiesis towards certain lineages at the expense of others.
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Patients with primary Hemophagocytic Lymphohistiocytosis (HLH) have defects
in the machinery associated with cytotoxicity of functions of T and natural killer (NK)
cells. They develop profound cytokine storm induced inflammation upon infection with
various pathologic agents. (Zhang et al., 2014a) By being unable to clear the infection,
the immune system is constantly bombarded with increasing levels of pathogenic stimuli
leading to release of high levels of IFN-γ, TNFα and other inflammatory cytokines.
Macrophage activation syndrome is a form of HLH that associates with rheumatologic
disorders including systemic lupus erythematosus and juvenile idiopathic arthritis.
(Zhang et al., 2014a) While it is still unclear why some lupus and arthritis patients
develop macrophage activation syndrome, lupus in particular is associated with the
immune system responding to apoptotic debris in a pro-inflammatory manner. Apoptotic
debris engulfed by phagocytic cells can stimulate TLR9 and in abnormal cases, drive an
adaptive immune response. (Biermann et al., 2014; Munoz et al., 2010; Zhang et al.,
2010) Plasmacytoid and traditional dendritic cells respond to the apoptotic debris
releasing both type 1 and type 2 interferons which drive further inflammation. (Biermann
et al., 2014) Many HLH patients have decreased peripheral B and T cell counts as well as
poor rates of bone marrow engraftment upon transplantation, suggesting that the
hematopoietic compartment is altered during inflammation. (Hinze et al., 2010; Sumegi
et al., 2011)
A variety of viral infections are linked to induction of aplastic anemia with
decreases in erythropoiesis, leukopoiesis, and thrombopoiesis. The viruses associated
with aplastic anemia in humans are heterogeneous and include parvovirus B19, Epstein3

Barr virus, cytomegalovirus, human immunodeficiency virus, dengue, measles virus and
hepatitis C. (Nakao et al., 1989; Ozawa et al., 1987) While the patterns of infection
among these viruses vary, they all induce high levels of IFN-γ, an inverted cluster of
differentiation (CD) 4:8 ratio and increased CD8 cytotoxicity. (Nakao et al., 1989; Ozawa
et al., 1987) Some of these viruses directly infect bone marrow progenitor cells leading to
disruption of normal hematopoiesis. Others alter the ability of bone marrow stromal cells
to support normal hematopoietic development in response to various inflammatory
cytokines and stimuli. (Manchester et al., 2002; Rosenfeld and Young, 1991; Simmons et
al., 1990; Young et al., 1987)
Multicentric Castelman’s disease is a lymphoproliferative, cytokine storm
disorder sometimes associated with human herpes virus-8. Idiopathic, or non-human
herpes virus-8 associated, multicentric Castelman’s disease is a diagnosis of exclusion
when other autoimmune, infectious, and neoplastic disorders are ruled out. (Fajgenbaum
et al., 2014) In this disorder, polyclonal lymphocytes become highly activated and
produce high quantities of various cytokines. The most common dominating cytokines
are IL-6 and type 1 interferons. (Muskardin et al., 2012) The cytokine storm and side
effects of the various chemotherapy and immuno-regulatory therapies severely alter the
hematopoietic compartment leaving patients immuno-suppressed post resolution of the
inflammatory periods.
A variety of infectious, autoimmune, and neoplastic conditions can induce
hyperinflammation. Patients with these inflammatory disorders display widespread organ
damage with variations depending on the inciting factor and the dominating cytokines
4

within the inflammatory cascade. Many of them also have alterations in hematopoiesis
and develop prolonged lymphopenias leaving the patients immuno-suppressed even after
recovery from the initiating incident. How inflammation alters hematopoiesis and the
long-term ramifications of these changes are still unclear.

Normal murine B and T lymphopoiesis
The progression from undifferentiated hematopoietic stem cell to mature
lymphocyte has been well characterized in murine models. During non-inflammatory
conditions, hematopoietic stem cells differentiate towards the lymphoid lineage losing
long-term self-renewal capabilities. These cells are termed multipotent progenitors.
(Beaudin et al., 2014; Luc et al., 2008) A subset of these multipotent progenitors
upregulate FMS-like tyrosine kinase 3 (Flt3) and are termed lymphoid primed
multipotent progenitors (LMPP). These LMPPS have no erythroid and megakaryocyte
potentials and limited myeloid potential.(Beaudin et al., 2014) Some of these LMPPs
migrate further towards the lymphoid lineages, upregulating IL-7Rα and are termed
common lymphoid progenitors (CLPs). These CLPs are defined as being LineageSca1intcKitintIL-7Rα+Flt3+. (Harman et al., 2008) They express high levels of the
transcription factors homeobox A9 (Hoxa9) and transcription factor 3 (E2A), which
contribute to upregulation of the cell surface receptors Flt3 and IL-7 receptor α (IL-7Rα)
whose ligands further support lymphoid development.(Bain et al., 1994; Gwin et al.,
2013a; Rolink et al., 1999; Seet et al., 2004) CLPs however are a heterogeneous
population; CLPs expressing Ly-6D+, are exclusively committed to the B cell lineage in
5

vivo, while the Ly-6D- CLPs can give rise to B, T, NK, or dendritic cells. (Allman et al.,
1999; Inlay et al., 2009; Mansson et al., 2010) These Ly-6D+ CLPs retain the ability to
generate T cells in vitro on OP9-dl1 cultures but do not generate T cells in vivo by
intrathymic injection. (Inlay et al., 2009) The Ly-6D+ CLPs begin to express high levels
of early B cell factor 1 (EBF-1), which specifies the B cell fate and turns on paired box 5
(PAX5) and other B cell factors that are important for initiating and maintaining the B
cell program. (Lin and Grosschedl, 1995; Pongubala et al., 2008; Rolink et al., 1999; Seet
et al., 2004; Tsapogas et al., 2011) As these B cell promoting transcription factors are
turned on, the progenitors also turn on recombination activating gene (RAG) and
rearrange the heavy chain of the B cell receptor (BCR). (Allman et al., 1999) Pro B cells
are committed to the B cell lineage and express CD19, CD93, protein tyrosine
phosphatase receptor type C (B220), and CD43. (Hardy et al., 1991) Upon successful
rearrangement of the heavy chain, these cells downregulate CD43 and undergo several
rounds of proliferation as Pre B cells. After successful rearrangement of the light chain,
the progenitors express surface IgM and are considered Immature B cells. (Hardy et al.,
1991) These cells can then leave the bone marrow and finish development in the spleen.
These peripheral developing B cells are termed Transitional B cells and are differentiated
by their expression of surface IgM and CD23. Stimulation of Transitional 1 or 2 B cells
through their B cell receptor leads to apoptosis while stimulation of the more mature
Transitional 3 cells leads to proliferation and further maturation, suggesting that
downstream signaling fates are changed as cells mature. (Carsetti et al., 1995)
Unlike B cell development, potential T ell progenitors must leave the bone
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marrow and travel through the circulation to the thymus where they receive instructing
signals that drive the T cell fate. These thymic settling progenitors can arise from the Ly6D- CLPs or straight from the LMPPs. (Chi et al., 2009) Of these early progenitors, those
that express the chemokine (C-C motif) receptors (CCR) CCR7 and CCR9 are able to
successfully home to the thymus where high levels of notch ligands on the thymic stroma
initiate the T cell transcriptional program while also repressing factors important for B
cell development. (Pui et al., 1999; Zhang et al., 2014b; Zlotoff et al., 2010) These
thymic settling progenitors are positive for stem cell growth factor receptor (cKit) but
negative for CD25, CD4 and CD8a and are termed early thymic progenitors (ETP).
(Bhandoola et al., 2007) ETPs retain NK and dendritic cell (DC) potential. The ETPs
then begin to express CD25 and are termed double negative (DN) 2 cells. As cKit
expression decreases, the cells lose DC potential. (Germain, 2002) The CD25+ cKit- cells
are the DN3 thymocytes, which undergo selection for the T cell receptor. These cells can
mature into two broadly different T cell lineages, the gamma-delta T cells and alpha-beta
T cells, named by their T cell receptor (TCR) expression. DN3 cells that successfully
rearrange the gamma-delta TCR go on to become mature gamma-delta T cells.
(Rothenberg, 2000) DN3 cells that successfully rearrange the beta chain progress to the
DN4 stage where they downregulate CD25 and prepare to upregulate CD4 and CD8a.
(Bhandoola et al., 2007; Germain, 2002) The CD4 and CD8a double positive cells (DP)
then undergo rearrangement of the alpha chain and express the full alpha-beta TCR on
their surface. Cells successfully rearranging TCRs enter positive selection where the
affinity of the newly arranged TCR for self-peptide-major histocompatibility complexes
7

is assessed. These DP cells are highly susceptible to apoptosis as they become refractive
to IL-7, a pro-survival cytokine, due in part to decreased IL-7 receptor expression.
(Ribeiro et al., 2013) DPs are therefore sensitive to glucocorticoids and other external
stimuli that induce apoptosis. More than 90% of these DP thymocytes undergo death by
neglect due to non-appropriate TCR rearrangements. (Brewer et al., 2002; Lu et al., 2000)
DP cells that successfully undergo positive selection progress to the CD4 and CD8a
single positive T cell lineages where they undergo negative selection for auto-reactive
TCRs and exit the thymus.

B and T lymphopoiesis during inflammation
Depending on the inflammatory model and which cytokines are produced,
different components of hematopoiesis are impacted. In a model where mice are
immunized with nitro phenol-chicken gamma globulin in incomplete Freund’s adjuvant,
both bone marrow B lymphopoiesis and myelopoiesis are altered. The B cell defect is due
in part by migration of some B cell precursors to the spleen. (Borrow et al., 2005; Ueda et
al., 2005; Ueda et al., 2004) The mobilization was revealed to be due to TNFα mediated
decreases in C-X-C motif chemokine ligand (CXCL) 12, which is important for
maintaining the B cell niche in the bone marrow. (Ueda et al., 2005; Ueda et al., 2004)
While CXCL12 levels recover within 8 days post-immunization, it is unclear how
repeated exposure to adjuvant-induced inflammation would alter TNFα and CXCL12
levels. In this same model, IL-1 or treatment with pertussis toxin, a broad chemokine
receptor blocker, increases granulopoiesis, leading to a net shift in production of
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granulocytes. (Ueda et al., 2005; Ueda et al., 2004) This may be due to the decrease in B
lymphopoiesis opening up space for increased granulopoiesis in the marrow or to
independent actions of differing cytokines. In T cell development, TNFα and IL-1 have
been shown to increase expression of CD25 in fetal thymic organ cultures. Blockade of
TNFα and IL-1 leads to decreased CD25 expression and impaired development of DP
thymocytes. (Zuniga-Pflucker et al., 1995) These data suggest that TNFα and IL-1 have
differing affects on B and T lymphopoiesis.
Studies looking at cultures of multipotent progenitors in vitro found that addition
of recombinant IL-6 to single cell cultures inhibited B cell potential but increased
myeloid potential. (Jenkins et al., 2007; Maeda et al., 2010) However, when single RAG+
early lymphoid progenitors were plated, addition of IL-6 increased B cell yields. (Maeda
et al., 2005) This suggests that IL-6 acts differentially on multipotent progenitors to
inhibit lymphoid fates, but once the cell is already committed to the lymphoid lineages, it
may enhance differentiation or proliferation. In an in vivo mouse model of lupus with
high levels of serum IL-6, mice had significantly decreased bone marrow B cell and CLP
numbers, which were restored when the mice were crossed to an IL-6 null background.
(Maeda et al., 2009) In a different mouse model with increased IL-6 receptor signaling,
thymocytes expressed higher levels of IL-6 transcripts and proteins than WT controls.
(Jenkins et al., 2007) The thymocytes also expressed higher levels of IL-6Rα suggesting
that they are both making and responding to IL-6 in an enhanced manner. Surprisingly,
these mice had increased thymic cellularity yet decreased percentages of DPs suggesting
that different thymocyte subsets also react differentially to IL-6. (Jenkins et al., 2007)
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These studies suggest that IL-6, like BCR and TCR signaling, has varying effects
depending on the stage of development of the precursor.
Type 1 interferons significantly alter hematopoiesis in a lymphocytic
choriomeningitis virus (LCMV)-WE model of infection. Three days after infection with
LCMV-WE, wildtype (WT) and IFN-γR knockout (IFN-γRKO) mice had <1% normal
bone marrow cellularity, with impaired abilities to generate granulocytes, erythrocytes,
and megakaryocytes. IFNα-RKO mice, however, mimic uninfected controls with normal
rates of hematopoiesis. (Binder et al., 1997) In another study looking at exogenous
treatment of IFNα2/α1 in neonatal mice, B lymphopoiesis was severely impaired and Pre
B cells exhibited decreased proliferation in response to IL-7. (Lin et al., 1998)
Thymopoiesis was also affected in this model, with the largest thymocyte reductions
occurring in the DP compartment. (Lin et al., 1998) However, it is unclear if these
decreases are a direct effect of the interferons on the precursor cells. Administration of
type 1 interferons to fetal thymic organ cultures lead to decreased thymic cellularity with
the largest decrease occurring at the DN3 stage, suggesting a block during beta chain
rearrangement. (Baron et al., 2008) However, administration of recombinant type 1
interferons to OP9-dl1 fetal derived hematopoietic stem cell co-cultures lead to a block in
T cell development at the DN1 stages with increased annexin-V staining cells. Together,
these data suggest that high levels of type 1 interferons impair lymphopoiesis at multiple
stages of T and B cell development in vivo and in vitro.
IFN-γ also inhibits lymphopoiesis in in vivo and in vitro models. B lymphopoiesis
was diminished in T cell protein tyrosine phosphatase null mice due to aberrant stromal
10

cell secretion of IFN-γ. The Pre B cells from these mice also demonstrated impaired
proliferation in response to IL-7, suggesting IFN-γ may be inhibiting responses to prosurvival cytokines. (Bourdeau et al., 2007) However, Pre B cells kept in culture with IL-7
and IFN-γ did not show increased rates of apoptosis within the first 48 hours in culture.
(Bourdeau et al., 2007) Transgenic mice expressing IFN-γ under the Ig-lambda enhancer
had varying phenotypes, with some mice becoming moribund while others remained
stable. These mice have severe defects in B lymphopoiesis and severe B cell loss in the
periphery. (Young et al., 1997) They also have increased expression of IFN-γ in the
thymus and increased thymic cellularity with higher numbers of both CD4 and CD8
single positive thymocytes but significantly fewer numbers of DPs. (Young et al., 1997)
The increase in single positive thymocytes may be due to proliferation of precursors in
response to IFN-γ or increased homing of mature T cells via the circulation.
Histologically, thymii from healthy transgenic mice were normal while those from
moribund transgenic mice showed severe atrophy, possibly due in part to stress and
glucocorticoid release. (Young et al., 1997) Together these data suggest that IFN-γ
inhibits IL-7 responsiveness and B and T lymphopoiesis, but it is unclear whether it is
acting directly on the precursors.
Another report looking at the effects of microbial products on B lymphopoiesis
found that stimulation through TLR9 with CpG or acute herpes simplex virus infection
leads to lower Pre B cells but increased bone marrow plasmacytoid dendritic cell
numbers. (Welner et al., 2008) While the reduction in B cells was dependent on TLR9
signaling, TNFα also played a partial role in mediating the decrease in B cell precursors
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in the bone marrow. However it but did not contribute to the increase in dendritic cells,
suggesting that they are not entirely reciprocal processes. In addition to decreased B
lymphopoiesis in vivo, CpG or herpes simplex virus administration appeared to alter the
lineage potential of CLPs in these models when they were placed in in vitro cultures.
(Esplin et al., 2011) However, CLPs are a heterogeneous population and it is unclear if
the inverse effects on B and dendritic cells are due to skewing of progenitors from one
fate to another, or if the Ly-6D+ CLPs are decreased, thereby biasing the inflammatory
CLP population towards Ly-6D- CLPs with DC potential.

Together these findings

suggest that multiple inflammatory factors, including TLR9 and TNFα, reduce bone
marrow B lymphopoiesis, yet they may not be the same factors directly leading to the
increase in dendritic cells. In the thymus, both TLR3 and TLR4 high dose stimulation is
associated with decreased thymic output and decreased DP thymocytes. However, these
models are associated with very high levels of pro-inflammatory cytokines and
glucocorticoids, which can also affect thymopoiesis. The direct effect of TLR signaling
on thymopoiesis remains unclear. (Baron et al., 2008; Billard et al., 2011)
In summary, prior work in the field has elucidated roles for a variety of cytokines
in inhibiting murine lymphopoiesis. However, for most cytokines, it remains unclear
whether they are acting directly on the precursors or on other immune cells. Specific
roles for TNFα and IL-1 in mediating migration of B cell precursors from the bone
marrow and inducing myelopoiesis respectively are known to inhibit normal bone
marrow lymphopoiesis. IL-6 appears to have opposing affects on B lymphopoiesis
depending on the stage of precursors exposed to IL-6 signaling. Whether or not this is
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due to changes in the downstream signaling is unclear. Type 1 and 2 interferons are also
known to affect lymphopoiesis although it is not known which cell type they are acting
on and whether physiologic amounts that could be seen during inflammation would have
similar inhibitory effects. TLR signaling also impairs lymphopoiesis but it is not clear at
which stages of development these inflammatory mediators are acting or whether they are
acting directly on B and T cell progenitors. In many of these cases it is also uncertain
how the inflammation is preventing normal B lymphopoiesis, whether by skewing or
progenitors away from lymphoid lineages, or by inducing apoptosis or migration from the
bone marrow.

Our model of systemic inflammation
In our model of systemic inflammation, we inject mice repeatedly with CpG, the
TLR9 agonist, five times over the course of ten days (Figure 1). These mice develop
systemic inflammation including splenomegaly, hepatitis, weight loss and pancytopenias,
specifically including decreased lymphocyte counts. By using genetically modified
knockout mice, we are able to characterize the direct effects of TLR9 and IFN-γ on B and
T lymphopoiesis at multiple stages of development in vitro and in our in vivo model of
cytokine storm. Since many infectious and autoimmune syndromes result in sustained
TLR9 stimulation and IFN-γ production, understanding the effects of hyperinflammation
on hematopoiesis is important for questions of pathogenesis as well as development of
possible therapeutic interventions to restore homeostasis.
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Chapter 2
Materials and Methods

Mice.
6 week to 12 week old mice were used throughout these studies. No differences in
sex or age were noted across experiments. C57BL6, C57BL/6.SJL IFN-γKO and IFNγRKO mice were obtained form Jackson Laboratories. TLR9KO and IFN-αRKO mice
were used as previously described and bred in our colony. (Hemmi et al., 2000; Leitner et
al., 2006) Bone marrow chimeras were administered 950 greys of gamma irradiation
followed by intravenous injection of 4-7 million bone marrow cells. Chimeric mice were
allowed 10 weeks to rest before use in experiments. Mice were maintained at the
University of Pennsylvania and Children’s Hospital of Philadelphia animal facilities. All
procedures were performed with consent from institutional ethics boards.

Antibodies and flow cytometry.
The lineage panel included antibodies against TCRβ, CD3, CD19, B220, NK1.1,
CD11c, CD11b, GR-1 (Ly-6C and Ly-6G), Ter119, FcεR, and CD8α. Aqua live dead
was used to visualize dead cells. All populations were first gated on forward and size
scatter to limit dead cells and doublets. Samples were then gated as Aqua low for live
cells. Antibodies were obtained from Biolegend, eBioscience, and BD Biosciences. Cells
were run on LSRII/II or FACS Aria sorters at the University of Pennsylvania flow
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cytometry core. FACS data were analyzed using FlowJo software.

Mouse models and isolation of samples.
Mice were injected intraperitoneally on days 0, 2, 4, 7, and 9 with phosphate
buffered saline (PBS), 50µg CpG 1826 (synthesized by IDT), or 10ηg IFN-γ (peprotech)
in 200 or 100µl of volume. On day 10 mice were euthanized and organs were taken for
analysis. In the 4-day model, mice were injected with PBS or 50µg CpG on days 0, 1, 2
and 3 and taken down on day 4. In the single dose model, mice were injected with PBS or
100µg CpG and taken down 48hrs later. In the LCMV-Armstrong model, mice were
infected with 2x105 plaque forming units and taken down 8 days later. All injections were
performed intraperitoneally. Two tibias and femurs per mouse were flushed using a 27.5
gauge needle with cold PBS. To ensure full and equal removal of cells, bones were
dissected open and any remaining cells were flushed out. Red blood cells were lysed
using ammonium chloride-potassium bicarbonate lysis buffer. Thymi were removed by
careful dissection and dissociated using fine-tipped forceps and vigorous pipetting with
cold PBS.

in vitro culture assays.
OP9 and OP9-dl1 stromal cells were used essentially as described. (Cho et al.,
1999; Schmitt and Zuniga-Pflucker, 2006) Both B and T cell cultures were supplemented
with 10 ηg/ml of IL-7, Flt3l, and stem cell factor (SCF) (peprotech). For dendritic cell
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cultures, wells were supplemented with 1 ηg/ml IL-7, 100ηg/ml Flt3l, and 10ηg/ml SCF.
OP9 and OP9-dl1 cells were plated at 20,00 cells/ml on day -2 and irradiated with 25
grey gamma irradiation on day 0. Stromal cells rested for 2-6 hours before media was
changed and 500 CLPs or 1000 Pro or Pre B cells were plated per well. Ly-6D+, Pro, and
Pre B cell co-cultures were allowed to grow untouched for 7-9 days and Ly-6D- cocultures for 13-15 days. Dendritic cell cultures were taken down on day 8. When used,
CpG was administered at 0.6µg/ml and IFN-γ at 100ρg/ml to individual cultures. Cell
numbers from OP9 experiments represent the number of events collected per volume per
time for a given well to allow for comparison.

Statistical Analyses.
Student’s t-tests were performed for all single comparisons. For data with
multiple comparisons, 1-way ANOVAs were performed with post-hoc analyses. For data
comparing two independent variables, 2-way ANOVAs were performed using Prism
software.

Affymetrix Microarray.
Mice were treated with PBS (n=3) of CpG (n=3) as described above. On day 10
Ly-6D- and Ly-6D+ CLPs were sorted separately from each mouse directly into lysis
buffer from the Qiagen RNAeasy Micro kit Plus using a FACS Aria. Ribonucleic acid
(RNA) isolation was performed in accordance with the Qiagen protocol. RNA was
purified using the (deoxyribonucleic acid (DNA)se treatment kit from Qiagen. Further
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analysis and processing of the RNA for quality, amplification and hybridization to the
mouse Affymetrix ST 2.0 Chip were performed by the NAPcore at the Children’s
Hospital of Philadelphia as previously described. (Canna et al., 2014) Microarray data
have been uploaded to the Gene Expression Omnibus repository (GEO accession number
will be provided upon acceptance). The array dataset was modeled using a 2-way
comparison of the Ly-6D- versus Ly-6D+ and PBS versus CpG. Principle component
analysis was performed using Partek Genomics Suite. Genome-wide significant genes
from the Ly-6D- PBS vs. CpG comparison were analyzed with the Ingenuity Pathway
Analysis program using a cutoff of a p value less than 0.00001 and an absolute value Z
score greater than or equal to 2.

Quantitative real-time polymerase chain reaction (qRTPCR)
Mice were treated with PBS (n=3) or CpG (n=3) and RNA was isolated from
sorted CLPs as described above. cDNA was made according to manufacturers
instructions (Superscript III First-Strand Synthesis System, Invitrogen). qRTPCR was
performed using the LifeTechnologies protocol. Primers were obtained from Applied
Biosciences. Real time PCR reactions were done using an ABI700 sequence detection
system and the 2XSYBR green master mix according to the manufacturer’s
specifications. The delta-delta CT method was used to quantify results. Values for each
gene were normalized to β -actin and one of the PBS treated samples for fold change
comparison.
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Chapter 3.
Systemic inflammation impairs lymphopoiesis

Introduction
While it is known that hematopoiesis is altered during severe inflammation, we
wanted to pursue how IFN-γ and TLR9 alter B and T lymphopoiesis. Our lab has two
models of systemic inflammation. One involves TLR9 stimulation by CpG, and the other
involves LCMV-Armstrong infection of perforin null mice.
In our primary model, mice are stimulated with CpG 5 times over the course of 10
days. These mice develop the signs and symptoms of cytokine storm disorders including
peripheral pancytopenias, splenomegaly, hepatitis, and weight loss but do not become
moribund or require euthanasia. (Behrens et al., 2011; Canna et al., 2014; Canna et al.,
2013) Prior work from our lab has characterized the serum cytokine levels and found that
IFN-γ, IL-12, IL-6, and type 1 interferons are produced as well as the anti-inflammatory
cytokine IL-10.34, 36 We also wanted to know if shorter courses of CpG could result in
similar alterations in hematopoiesis, as the longer model may produce excess
inflammation thereby complicating the roles individual factors play in directly mediating
decreased lymphopoiesis. The comparison of shorter and longer models may also reveal
whether inflammation is acting at multiple stages across development since it takes time
for early progenitors to move through lymphoid developmental stages. We therefore also
gave doses of CpG every day for 4 days as well as a larger, single dose to different
cohorts of mice.
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The second model involves infection of perforin null mice with LCMVArmstrong. While normal WT mice can clear this infection, these knockout mice are
unable to kill infected cells and therefore are cannot shut down the immune response.
These mice develop many of the same signs and symptoms as repeated CpG administered
mice, yet to a larger degree. In fact, many of these mice lose too much weight or become
moribund and require euthanasia. While LCMV is an RNA virus and therefore does not
signal through TLR9, it stimulates other TLRs resulting in very high levels of type 1 and
2 interferons. (Pien et al., 2002; Wherry et al., 2007) Because LCMV is a live viral
infection; it induces inflammation through multiple immunologic receptors in addition to
TLRs. (Jung et al., 2008) Since LCMV infection results in fulminant inflammation, the
stress response is activated producing glucocorticoids, which contribute to alterations in
hematopoiesis, specifically reductions in lymphopoiesis.
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Chapter 3
Results

Repeated CpG inhibits the developing B and T cell compartments.
We first induced sustained TLR9 driven inflammation in mice over a 10-day
period as previously described. (Behrens et al., 2011; Canna et al., 2014; Canna et al.,
2013) On day 10, we examined the bone marrow and found decreased total cellularity
(Figure 2A). Interestingly, this was driven primarily by a reduction in the CD19+ and
erythroblast compartments while other lineages were grossly intact (Figure 2B and data
not shown). This suggests that repeated CpG induced inflammation is not affecting gross
hematopoiesis, but that it is acting directly on the B cell lineage. As the B cell
compartment in the bone marrow includes both mature recirculating B cells as well as
immature developing cells, we further analyzed the B cell compartment and found that
Pre, Pro, and Immature B cells were all decreased approximately 10-fold in the mice
receiving CpG compared to PBS treated controls (Figure 2C). As all stages of committed
B cell precursors were down, we looked one stage earlier at the CLPs and found that the
lymphocyte antigen 6 complex locus D (Ly-6D) negative, or uncommitted CLPs were
relatively normal in number, but the Ly-6D+, or B cell committed CLPs were
significantly decreased (Figure 2C). We therefore also wanted to know if there would be
a similar effect in T lymphopoiesis since B and T cells develop from the same early
progenitors and are susceptible to many of the same insults. We found that thymic
cellularity was also significantly decreased (Figure 3A). Since many stressors specifically
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alter the DP stage of thymic development, we characterized thymocyte numbers based on
CD4, CD8, cKit, and CD25 expression and found that all stages were decreased without
any obvious blocks in development (Figure 3B). Concurrent decreases in T and B
lymphopoiesis could be due to alterations in early lymphoid development that are carried
through both lineages, or it could be due to inflammatory factors acting separately on
both lineages.

4 day CpG diminishes B and T cell lymphopoiesis.
In our 10-day model it is possible for decreases in early stages of hematopoiesis to
carry through into later stages. We therefore wanted to look in a shorter model of CpG
induced inflammation for similar or lessened changes in B and T cell development. First,
we wanted to ensure that total bone marrow changes mimicked those found in the 10-day
model. To test this we injected mice with CpG 4 on consecutive days and took down the
mice on day 5. We found similar reductions in total bone marrow cellularity to the 10-day
model (Figure 4A), which was also primarily driven by decreases in the B cell
compartment (Figure 4B). Within 4 days, a lone defect in the CLP compartment should
not lead to 10 fold decreases in Immature B cells like in the 10 day model. To test if this
was the case, we looked at B cell precursor numbers in these mice and found that unlike
the 10-day model, only Pre and Immature B cells were significantly decreased (Figure
4C). This suggests that the CpG induced inflammatory environment can act at the later
stages of bone marrow B cell development. Thymic cell counts were also similarly
decreased (Figure 4D), suggesting that the factors driving decreased Pre and Immature B
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cells and T cells in the 10 day model are induced within 4 days and do not require
protracted dosing to mediate their effects. The factors affecting the CLPs, however, do
require a longer dosing protocol.

Single dose CpG diminishes myeloid, not lymphoid compartments.
As four consecutive doses sufficiently impaired the lymphoid compartments, we
wanted to know if a single dose would have similar effects. We therefore gave one larger
dose of CpG and looked 48 hours later at the bone marrow and thymus. While total bone
marrow cellularity was still decreased (Figure 5A), surprisingly this was due to
diminished myeloid compartments, as the number of B cells did not change (Figure 5B).
Thymic cellularity was also not significantly decreased (Figure 5C). Together this
suggests that the single dose of CpG was not sufficient to alter lymphopoiesis in the same
manner as in a sustained CpG model.

LCMV induced cytokine storm severely impairs the bone marrow and thymic
compartments.
We then wanted to test whether the bone marrow and thymic compartments were
altered in the more severe inflammatory environment of uncontrolled infection. Perforin
null mice were infected with LCMV-Armstrong and taken down on day 8 corresponding
to the peak of the immune response in LCMV infected WT mice. Unfortunately, one
infected mouse was too sick and did not survive until day 8 preventing statistical analysis
for significance. When we looked at the bone marrow counts in the surviving mice, we
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found that bone marrow cellularity was decreased and that the B cell compartment was
severely inhibited (Figures 6A and 6B). We again looked at the thymus for reductions in
thymopoiesis and found severely decreased thymic cellularity (Figure 6C). These
findings suggest that LCMV induced cytokine storm inflammation impairs thymic
development and inhibits the B cell compartment in the bone marrow.
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Using various models and dosing methods, we have shown that lymphopoiesis is
inhibited during systemic inflammation. Interestingly, these data suggest that the
inflammatory environment is acting at multiple stages of B lymphopoiesis. It is reducing
numbers of Ly-6D+ CLPs, the earliest known stage of B cell commitment as well as
acting at the Pre and Immature B cell stages as evidenced in our 4 day CpG model.
Insults at each stage of development can also account for why Ly-6D+ CLPs decrease 2fold while Pro, Pre, and Immature B cells decrease 10-fold. Generally, small decreases in
early progenitors can be compensated for by the proliferative burst during later stages of
development. Our data suggest that the inflammatory environment is inhibiting lineage
development, blocking proliferation, or inducing apoptosis of progenitor cells.
Surprisingly, single dose CpG lead to significant reductions in myeloid populations but
not lymphoid populations in our model. This suggests that repeated TLR9 stimulation
induces unique factors that mediate lymphopoiesis.
As developing T cells are also reduced, factors could be acting early in lymphoid
development inhibiting both lineages. However, similar to B cells, reductions in early T
cell progenitors can be compensated for by the large proliferative capacity of the cells
that reach the thymus. (Zlotoff et al., 2010) While homing may also be affected during
inflammation, decreases across development suggest that there are alterations in the
thymic stromal compartments, such as is seen during systemic irradiation. (Zhang et al.,
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2014b; Zlotoff et al., 2011)
TLR9 stimulation produces a number of cytokines and it is possible that different
factors are acting at the various stages of B lymphopoiesis. The roles of TLR9 and IFN-γ
will be discussed in more depth in chapter 2. It is possible however, that type 1
interferons, IL-6, and TNFα could be contributing to the decreases seen in our model.
One possibility is that TNFα is reducing levels of CXCL12 that retains progenitors in the
bone marrow, thereby allowing them to migrate to the spleen. We however see decreased
total numbers of splenic B cells (data not shown), suggesting that this is not the only
explanation for the decrease in bone marrow B lymphopoiesis. Additionally, as thymic
subsets are equally decreased across development, it would suggest that TNFα is not
directly inhibiting CD25 expression or DP thymocyte development. Type 1 interferons
are also produced in our model and can diminish erythropoiesis as well as myelopoiesis
and lymphopoiesis. (Binder et al., 1997; Buechler et al., 2013) While we do see reduced
erythrocyte progenitors in the bone marrow of mice receiving repeated CpG, myeloid
populations are stable. Even though erythropoiesis is reduced in the bone marrow, it is
increased in the spleen and liver. Most of the extra-medullary hematopoiesis seen in the
spleens of our mice is in fact due to increased erythroblasts (data not shown). These
findings suggest that high dose type 1 interferons are not the sole factors mediating the
decrease in our models of inflammation. IL-6 is also produced in our model and may be
acting at the early stages of lymphopoiesis where it can diminish lymphoid potential.
(Maeda et al., 2005; Maeda et al., 2009; Maeda et al., 2010) It is unlikely the main
contributing factor, however, as it would increase later B progenitors in contrast to our
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data.
Severe inflammation acts as a stressor to the body producing steroid hormones
called glucocorticoids. At high doses, these steroid hormones have profound antilymphopoiesis effects. In B lymphopoiesis they are known to act primarily at the Pro and
Pre B cell stages as the cells undergo selection. (Andreau et al., 1998; Gruver-Yates et al.,
2014; Igarashi et al., 2005) This is also true in the thymus, where steroids have potent
effects inhibiting DP thymocytes that are undergoing positive selection. (Brewer et al.,
2002; Lu et al., 2000) While it is possible that steroids are contributing to the effects we
see in our CpG model, the decrease in CLPs and thymocytes across development suggest
they are not the sole factors blocking lymphopoiesis.
It is possible that TLR9 signaling alone drives these reductions in B
lymphopoiesis as all progenitors express TLR9. (Welner et al., 2008) However, we see
similar decreases in B cell precursors in perforin null mice infected with LCMV
suggesting that other TLRs and the broad inflammatory environment can also inhibit
lymphopoiesis. As LCMV is an RNA virus, it stimulates TLR3, TLR7 and TLR8, of
which TLR7 is expressed on lymphoid progenitors. (Sioud et al., 2006) LCMV infection
does produce high levels of IFN-γ, which is similar to our CpG model. Since LCMV
infection is a much stronger stressor than repeated CpG dosing, it is likely that steroids
are also playing a larger inhibitory role in this model.
Overall, these data suggest that CpG induced inflammation acts at multiple stages
of B cell development while also inhibiting T cell development. This may be occurring
by multiple mechanisms, including skewing of early progenitors away from the B
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lineage, decreased proliferation at the Pre B cell and DP thymocyte stages and increased
apoptosis. As thymopoiesis is also impaired, it suggests that global lymphoid
development may be diminished or that inflammatory factors act independently after
progenitors commit to separate lineages. Most likely, inflammation is doing both because
it acts at early and later stages of development. The decreases at multiple stages of
development are likely due to various inflammatory factors, including TLR9 signaling
itself, IFN-γ, type 1 interferons, IL-6, and TNFα.
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Chapter 4
TLR9 and IFNγR signaling directly impair B lymphopoiesis

Introduction
Early hematopoietic cells including CLPs and developing B cells are known to
express high levels of TLR9. (Welner et al., 2008) Data from Paul Kincaide’s lab
suggests that TLR9 stimulation of CLPs may divert these progenitors away from the B
cell lineage and towards the dendritic cell lineage. (Welner et al., 2008) While the CLP
population used in that paper is heterogeneous including both Ly-6D- and B cell
committed Ly-6D+ CLPs, it shows that CLPs can receive instructive signals through their
TLRs. We do know that the decrease in lymphopoiesis is dependent on global CpG
signaling through TLR9, as TLR9 null mice do not develop the signs of systemic
inflammation nor do they have decreased B or T lymphopoiesis (data not shown). It is
unclear however, whether TLR9 must signal on the lymphoid progenitors themselves or
whether it is signaling on other cells to release secondary factors that then mediate the
decreases in lymphopoiesis.
One candidate factor is IFN-γ. Our lab has also shown that IFN-γ is essential for
the full spectrum of disease to develop, as IFN-γR knockout (IFN-γRKO) mice are
protected from developing widespread inflammation and do not produce the array of
cytokines listed above.34, 36 The IFN-γ receptor is a heterodimer of two subunits, IFN-γR1
and IFN-γR2. (Bernabei et al., 2001; Jung et al., 1987) IFN-γR1 is expressed almost
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ubiquitously in the immune system, while IFN-γR2 is expressed on subsets of myeloid
cells, B cells, stromal cells and certain populations of T cells. (Gazit et al., 2013) Both
subunits are expressed on CLPs and B precursors. Early thymocyte precursors also
express IFN-γR, but decrease expression during thymic development until cells reach the
single positive stages. (Mingueneau et al., 2013) As stromal cells also express the IFNγR, it is possible that IFN-γ is directly acting to inhibit stromal cell release of cytokines
necessary to promote development. (Stagg et al., 2006)
In myeloid cells, it is well documented that TLR and IFN-γR signals can interact
and enhance the cellular response to either stimuli. In macrophages, IFN-γ exposure
primes cells to respond to TLR4 signaling. (Chen and Ivashkiv, 2010; Franklin et al.,
2009; Hu et al., 2008) IFN-γ priming causes less production of the anti-inflammatory
factor IL-10 and excess production of TNFα, IL-6, and IL-12. This occurs by a variety of
mechanisms, including increased expression of TLRs, enhanced downstream signaling,
as well as epigenetic modulation leading to increased and prolonged recruitment of TLR
signaling molecules to the promoters of inflammatory genes. Perhaps sustained TLR
signaling and IFN-γ production are required to drive the decreases in B lymphopoiesis,
which is why a single dose is insufficient compared to 4 or 10 days of dosing. It is
possible that IFN-γR and TLR9 signaling are acting synergistically directly at the level of
the lymphoid progenitors or on peripheral cells to produce a secondary mediator that
decreases B and T lymphopoiesis. We therefore assayed the roles of TLR9 and IFN-γR
signaling play in inhibiting B lymphopoiesis by using in vitro and in vivo models.
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CpG and IFN-γ stimulation differentially affect B and T cell growth in vitro.
As B cell precursors express both TLR9 and IFN-γR, we investigated which B
cell progenitors were affected by CpG and IFN-γ treatment using the established OP9 coculture system to eliminate confounding factors that may be present in vivo. (Cho et al.,
1999; Schmitt and Zuniga-Pflucker, 2006) Ly-6D- CLPs, Ly-6D+ CLPs, Pro, or Pre B
cells were cultured in B cell promoting conditions and administered PBS, CpG, or IFN-γ.
We found significant reductions in the number of B cells generated from Ly-6D+ CLPs,
Pro and Pre B cells that received CpG or IFN-γ compared to PBS (Figure 7A). To test if
treatment effects were specific to the B cell lineage, CLPs were also cultured in T cell
promoting conditions. Surprisingly, Ly-6D- CLPs receiving CpG yielded more T cell
precursors while IFN-γ still severely decreased T cell yields (Figure 7B). This suggests
that CpG and IFN-γ are acting via different pathways to alter CLP development.

TLR9 signaling directly inhibits B cell differentiation but increases T cell
differentiation in vitro.
To interrogate whether the CpG induced inhibition of B lymphopoiesis was acting
in a TLR9 intrinsic manner, we performed similar in vitro experiments using mixed
cultures of equal numbers of TLR9 sufficient and TLR9 deficient (TLR9KO) CLPs. In
the B cell promoting conditions, we found that only the TLR9 sufficient progenitors
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produced lower B cell yields while the TLR9KO cells yielded similar numbers in the
PBS and CpG treated groups (Figure 8A). We performed the same experiment in T cell
promoting conditions and found that only the TLR9 sufficient CLPs led to increased T
cell yields with CpG treatment, suggesting that TLR9 signaling directly alters the lineage
potential of CLPs (Figure 8B).

TLR9 extrinsic factors contribute to the decrease of B lymphopoiesis in vivo.
To determine if TLR9 signaling was the primary cause of the lymphopoiesis
defects in vivo, we made mixed bone marrow chimeras. We injected lethally irradiated
TLR9KO hosts with mixed 50:50 congenically marked WT/TLR9KO bone marrow and
waited 10 weeks for reconstitution before administering the 10-day CpG regimen. In
contrast to the in vitro data, we found that the TLR9KO B cell progenitors were not
spared, as Pre B cell numbers from mixed chimeras receiving CpG demonstrated similar
decreases in numbers of both wild type (WT) and TLR9KO precursors (Figure 9A). Pro
and Immature B cells yielded similar results to the Pre B cells (data not shown). This
suggests that in vivo, TLR9 intrinsic signaling does not decrease lymphopoiesis or that
the contribution of other TLR9 extrinsic factors mask the role of TLR9. While the
thymocyte data demonstrated an upward trend in numbers of cells seeing TLR9
stimulation, the changes were not significant suggesting that other factors are also acting
on thymopoiesis in vivo. These factors, including IFN-γ, may be inhibiting thymopoiesis
thereby masking a TLR9 intrinsic effect (Figure 9B).
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Type 2 but not type 1 interferons mediate decreases in lymphopoiesis.
Because IFN-γ is induced by in vivo TLR9 stimulation and it inhibited CLP
differentiation in vitro (Figure 7), we investigated whether IFN-γ was contributing to B
and T lymphopoiesis defects in vivo. We injected WT or IFN-γRKO mice with CpG or
PBS and found that the IFN-γRKO mice were protected from inflammation as they had
significantly smaller decreases in B cell progenitors compared to WT mice (Figure 10A).
This suggests that IFN-γ is one of the main mediators leading to decreased B cell
progenitors in vivo. It may be the confounding factor responsible for masking the TLR9
intrinsic effect. This is not true of all TLR9 induced cytokines, as mice lacking the IFN-α
receptor gene (IFN-αRKO) were not protected compared to the WT mice (Figure 10B).
The restoration of B cell precursors in IFN-γRKO mice was not complete, suggesting that
other signals also contribute to the defects in B lymphopoiesis. Thymic cellularity, in
contrast to B lymphopoiesis, was not dependent on type 1 or 2 interferons since both
IFN-αRKO and IFN-γRKO mutant mice had statistically similar decreases compared to
PBS controls, and the interaction coefficient was not significant (Figures 10C and D).
This suggests that B and T lymphopoiesis are differentially regulated by interferons.

Interferon gamma receptor signaling directly inhibits Ly-6D+ CLP development in
vitro.
To test if the decreases we saw in vitro with IFN-γ administration were IFN-γR
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precursor cell intrinsic, we used the same mixed culture strategy as before but with WT
and IFN-γRKO cells and IFN-γ administration. In these mixed cultures, we found that
only the WT cells yielded fewer B cells in response to IFN-γ, as the IFN-γR KO cell
yields were similar to cultures receiving PBS (Figure 11A). Since IFN-γ decreased T cell
yields when added to OP9-dl1 cultures, we wanted to test whether IFN-γ is acting
directly on the T cell precursors like it was acting on the B cell precursors. Using the
same mixed strategy as for B cells, we found that only the Ly-6D+ cultures demonstrated
a IFN-γR intrinsic decrease in T cell yields while both IFN-γRKO and WT cells
decreased in the Ly-6D- cultures (Figure 11B). Even though Ly-6D+ CLPs do not
generate T cells in vivo, they can in vitro. These data suggest that Ly-6D+ CLPs are more
sensitive to IFN-γ than Ly-6D-, and that the OP9-dl1 cells or T cell precursors produce
factors in response to IFN-γ that also decrease T lymphopoiesis.

Interferon gamma receptor signaling directly inhibits B cell development in vivo.
We then investigated whether a cell intrinsic IFN-γR response is the dominant
force leading to decreased B cell progenitors in vivo by making mixed IFN-γRKO and
WT congenically marked bone marrow chimeras. We used a 90% WT and 10% IFNγRKO mix since mice generated with fewer IFN-γ responsive cells do not generate the
full panel of cytokines normally seen in the sustained TLR9 inflammation model
(unpublished observations). We found that there was a statistically significant differential
in Pre B cell numbers in the CpG treated mice such that the IFN-γRKO B cells were less
affected than WT (Figure 12A). This suggests that there is a measurable cell intrinsic
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IFN-γR signaling event leading to decreased B lymphopoiesis during sustained TLR9
inflammation in vivo. Consistent with the results from the IFN-γRKO experiments
(Figure 10A), the IFN-γRKO cells in the chimeras also trended towards a smaller
decrease, emphasizing that IFN-yR signaling is not the only factor leading to decreased B
lymphopoiesis and perhaps unmasking a TLR9 effect.

IFN-γ and CpG act via distinct pathways to inhibit B lymphopoiesis in vivo.
Given that there appear to be different TLR9 and IFN-γR effects on B cell
development in vitro, we next investigated whether these two pathways interact in vivo,
particularly since previous work in innate cells found that IFN-γR and TLR9 signaling
can synergize at the epigenetic level. (Chen and Ivashkiv, 2010; Hu et al., 2008; Qiao et
al., 2013) To address this question, we used IFN-γ deficient mice (IFN-γKO), that are
capable of responding to IFN-γ but are unable to produce it, and examined how CpG,
IFN-γ or the combination of both stimuli affect B and T lymphopoiesis. The dose of IFNγ was selected to replicate serum levels of IFN-γ seen in WT mice treated with the
repeated CpG protocol. (Behrens et al., 2011) We observed that both CpG and IFN-γ are
capable of to reducing Pre B cell and thymocyte numbers (Figure 12B). However,
statistical modeling did not reveal a significant interaction effect, suggesting that they are
acting independently via additive and not synergistic pathways, corroborating our in vitro
data.
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Our data demonstrate that TLR9 has disparate effects on the B and T cell
lineages, impairing early progenitors from becoming B cells, yet enhancing their ability
to become T cells in vitro. One possibility is that TLR9 is acting at the level of the CLP
to skew precursors away from the B cell lineage, and perhaps towards the T cell lineage.
This may be intrinsic to each CLP or a result of general skewing of the population
towards CLPs with greater T cell potential since those with greater B cell potential are
decreased. As CpG also had inhibitory effects on plated Pre B cells, it suggests that it also
induces apoptosis or inhibits proliferation in later progenitors. This is in contrast to TLR9
signaling on mature B cells, which promotes maturation and induces proliferation.
(Guerrier et al., 2012) The differential effects of TLR9 on immature versus mature B
cells may be due to alterations in downstream signaling molecules or epigenetic changes
allowing TLR9 signaling factors to promote different outcomes. This differential
signaling is not unheard of, as immature B cells receiving signals through their BCR
undergo apoptosis while mature B cells are activated and undergo proliferation.
IFN-γ in contrast, had devastating effects on both B and T cell cultures of CLPs
suggesting that it is inducing apoptosis or preventing proliferation regardless of exposure
to B or T instructive signals. It had similar results on plated Pre B cells suggesting that
IFN-γ signaling effects do not change as the progenitors mature. Perhaps this strong IFNγ effect overwhelms the ability to detect an intrinsic TLR9 role in vivo in the mixed bone
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marrow chimera system. Surprisingly, even though type 2 interferons directly reduced B
lymphopoiesis, type 1 interferons did not. While type 1 and 2 interferons share similar
downstream signaling factors, IFN-γ is much more highly expressed in our model, which
may account for its dominating effects in vivo. (Canna et al., 2014; Canna et al., 2013)
IFN-αRKO null mice do however show slightly improved measures of systemic disease
including weight loss and anemia. (Canna et al., 2013) This suggests that Type 1
interferons are important for some aspects of inflammation, (Canna et al., 2014; Canna et
al., 2013) but may play a redundant role with IFN-γ in mediating decreased B
lymphopoiesis.
Interestingly, while TLR9 and IFN-γ are known to act via synergistic pathways in
macrophages, our statistical modeling data suggest that they are acting independently to
inhibit B lymphopoiesis. This is supported by our in vitro data where TLR9 signaling
encourages T cell development but IFN-γ inhibits both T and B cell development. TLR9
signaling appears to skew CLPs away from the B cell lineage while IFN-γ solely acts to
induce apoptosis or block proliferation. It may be possible that the common sites where
synergism is observed in myeloid cells, promoters of TNFα and IL-6 for example, are not
transcriptionally active in these early progenitors or are not main contributors responsible
for decreasing lymphopoiesis.
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Chapter 5
Introduction

The ability of TLR9 to enhance T cell potential but inhibit B cell potential
suggests that transcriptional changes may be are occurring within these progenitors
altering their lineage potential. Early hematopoiesis relies on complex interactions of
various transcription factors important for directing cells towards specific lineages.
Hoxa9 is a homeobox transcription factor important for early hematopoiesis. Hoxa9 null
mice exhibit lower numbers of peripheral myeloid and lymphoid cells. They also have
reduced clonogenic potential for erythroid and myeloid colony types with even larger
reductions in B cell outputs from lymphoid colonies. (Lawrence et al., 1997) One key
aspect of Hoxa9’s regulation of lymphopoiesis is control of Flt3 expression. (Gwin et al.,
2010) Hoxa9 null mice have very low levels of FLt3 expression, which accounts for part
of the reductions in lymphoid cells. (Gwin et al., 2013b) Hoxa9 is highly expressed at the
Ly-6D- CLP stage where it turns on genes important for B cell specification before
turning off allowing for further development. (Gwin et al., 2013a; Gwin et al., 2010;
Gwin et al., 2013b) Spleen focus forming virus pro-viral integration oncogene (Pu.1) is
another transcription factor important in hematopoiesis. Pu.1 mutant mice have normal
numbers of megakaryocytes and erythroid progenitors but display a multilineage defect
in myeloid and lymphoid lineages. (Scott et al., 1994) Pu.1 also controls expression of
IL-7Rα and is required for the generation of Pro B cells. (DeKoter et al., 2002) Another
transcription factor expressed early during development is Ikaros. Ikaros proteins act as
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transcriptional repressors and activators and in lymphoid progenitors contribute to
upregulation of Flt3 and IL-7Rα. (Georgopoulos et al., 1994) Ikaros mutant mice have
normal myeloid erythroid formation yet lack T, B, and NK cells as well as common
lymphoid progenitors .(Georgopoulos et al., 1994)
Once these early regulating transcription factors upregulate expression of Flt3 and
IL-7Rα, cells are directed towards the lymphoid fates retaining minimal myeloid
potential. Expression of E12 and E47, collectively known as E2A, is essential for B cell
development as E2A mutant mice have intact peripheral myeloid and T cell populations
but absent peripheral B cells and low numbers of CLPs. (Bain et al., 1994) E2A is also an
important regulator of IL-7Rα, which together turn on the transcription factor EBF-1.
(Seet et al., 2004; Tsapogas et al., 2011) EBF-1 plays a central role in B lineage
specification, regulating many of the genes associated with the B cell receptor and
immunoglobulin heavy chain recombination. (Lin and Grosschedl, 1995) While EBF-1
specifies the B cell fate, its induction of the transcription factor Pax5 solidifies B cell
commitment as Pax5 over-expressing cells can no longer generate T cells or
macrophages, (Souabni et al., 2002) and Pax5 mutant Pro B cells maintain multilineage
potential. (Nutt et al., 1999; Rolink et al., 1999)
Many of the same early genes important for B lymphoid development are
important for T cell development including Hoxa9, Pu.1, and Ikaros. One unique issue
during T cell development is the migration of uncommitted lymphoid precursors from the
bone marrow to the thymus. (Carlyle and Zuniga-Pflucker, 1998) Successful thymic
settling requires expression of chemokine receptors including CCR7 and CCR9. (Zlotoff
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et al., 2010) While loss of CCR7 and CCR9 reduces the numbers of early thymic
progenitors, total cellularity is near normal due to the large proliferative capacity of cells
that do successfully enter the thymic environment. (Zlotoff et al., 2010) Once these
progenitors settle the thymus, high levels of notch signaling instruct the T cell fate and
block factors important for the B cell and dendritic cell fates including E2A, Pax5, and
CCAAT/enhancer binding protein α. (De Obaldia et al., 2013; Pongubala et al., 2008; Pui
et al., 1999; Radtke et al., 1999), 66 Notch1 also induces the transcription factors hairy
and enhancer of split 1 and T cell factor -1 (TCF1), which silence other cell fates further
committing precursors to the T cell fate. (De Obaldia et al., 2013; Rapino et al., 2013;
Tomita et al., 1999; Weber et al., 2011)
Differentiation into the various subsets of dendritic cells requires either
granulocyte-macrophage colony stimulating factor or Flt3. Common lymphoid
progenitors that become DCs primarily become pDCs or lymphoid resident DCs. (Carotta
et al., 2010) High levels of Flt3 drive dendritic cell differentiation from lymphoid
precursors. Mice deficient in Flt3 or its downstream signaling molecule signal transducer
and activator of transcription 3 demonstrate markedly lower lymphoid resident and
plasmacytoid dendritic cells (pDC). (Kingston et al., 2009) Similar to T and B cells, Pu.1
and Ikaros play roles in dendritic cell differentiation from lymphoid progenitors. Induced
deletion of Pu.1 leads to decreased pDCs and conventional DCs (cDC) in part through
decreased expression of Flt3. (Carotta et al., 2010) Mice expressing low levels of Ikaros
have decreased peripheral pDCs but normal cDCs also due to an inability to respond to
Flt3 ligand. (Carotta et al., 2010) Expression of the E protein E2-2 specifies and
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differentiates dendritic cell precursors to the pDC lineage as E2-2 mutant mice have a
specific defect in the pDC compartment with normal cDC and B cell numbers. (Cisse et
al., 2008) Correspondingly, pDCs require lower levels of the protein inhibitor of DNA
binding 2 (Id2), which is a direct inhibitor of E proteins. Other DC lineages express high
levels of Id2, corresponding to their low levels of E2-2. (Jackson et al., 2011) E2-2 also
acts to turn on interferon regulatory factor 8, which induces expression of TLR9 and type
1 interferons. (Schroder et al., 2007; Tailor et al., 2007) Type 1 interferons in turn further
promote pDC differentiation from CLPs. (Chen et al., 2013)
The ability of TLR9 to enhance T cell potential but inhibit B cell potential in our
model suggests that transcriptional changes may be are occurring within early lymphoid
progenitors thereby altering their lineage potential. Early hematopoiesis relies on
complex interactions of various transcription factors important for directing cells towards
specific lineages. We wanted to look for alterations in lineage potential of CLPs in our
CpG treated mice.
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Chapter 5
Results

Exposure to CpG induced inflammation in vivo skews CLPs away from the B cell
lineage and enhances T cell differentiation in vitro.
To determine if the complex in vivo TLR9 induced inflammatory milieu causes
lineage skewing, we sorted Ly-6D+ and Ly-6D- CLPs from mice receiving repeated CpG
or PBS injections and placed them in the OP9 culture system under B, T or dendritic cell
promoting conditions. No further CpG or inflammatory cytokines were given during the
in vitro culture process. We found that Ly-6D+ CLPs isolated from CpG treated mice
yielded significantly fewer B cells than those from the PBS treated mice in B cell
conditions (Figure 13A).

In contrast, we found that the CLPs exposed to the

hyperinflammatory environment demonstrated enhanced T cell potential (Figure 13B).
This may occur in a cell intrinsic manner or by skewing of the population towards CLPs
that are predisposed to generate T cells. CLPs destined to generate T cells may express
higher levels of the thymic homing receptors CCR9 and CCR7. To test this we stained for
CCR9 levels but found lower CCR9 expression on Ly-6D- CLPs form CpG treated mice
(Figure 13C). To test if the increase in T cell yields was unique to the T cell lineage, we
also tested DC potential. Ly-6D+ CLPs, while able to differentiate into T cells in vitro
generated minimal dendritic cells even under dendritic cell promoting conditions. They
did generate B cells however, which showed similar results to the B cell conditions
(Figure 14A). Ly-6D- CLPs gave rise to very few B cells but did generate both pDCs and
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cDCs (Figure 14B). Surprisingly, exposure to the CpG inflammatory environment did not
alter DC yields compared to PBS treated mice.

CpG induced inflammation alters the B cell transcriptional program.
We next assayed the transcriptional program of CLPs during inflammation for
factors that might explain the skewing away from the B cell lineage. To get a global
transcriptional view, we analyzed mRNA expression from Ly-6D- and Ly-6D+ CLPs
from repeated CpG or PBS treated mice by microarray. 3 mice were used per group and
samples were run individually. Principle component analysis across all 4 groups of
samples demonstrated that the four groups cluster independently, suggesting different
transcriptional programs based on both stage of development and the presence of
inflammation (Figure 15A). In order to look for differentially expressed genes between
the different groups, we performed a two-way ANOVA. Using a false discovery rate of
20% (Benjamini-Hochberg), we found 2734 genes differentially expressed in Ly-6Dversus Ly-6D+ CLPs and 382 genes differentially expressed between PBS and CpG
treatments, 225 of which were in both lists (Figure 15B). Thus, approximately 60%
(225/382) of the genes altered by sustained TLR9 induced inflammation are also genes
that appeared to be altered during the transition from the Ly-6D- to Ly-6D+ stage of B
cell development.
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Ingenuity Pathway Analysis suggests Hoxa9 is down-regulated in Ly-6D- CLPs
during CpG induced inflammation.
Focusing on the Ly-6D- CLPs, which have in vivo multi-lineage potential, we
explored potential factors that could account for the pattern of differentially expressed
genes between PBS and CpG exposures using the upstream analysis module of the
Ingenuity Pathway Analysis (IPA) program. We found that the transcription factor Hoxa9
was predicted to have the most down-regulated activity (Table 1). This was of particular
interest, as Hoxa9 is described to be an important B cell lineage coordination factor.
(Gwin et al., 2013a; Gwin et al., 2010; Gwin et al., 2013b; Izon et al., 1998) In contrast,
we did not find significant evidence suggesting changes in Pu.1, E2A, Ikaros, or E2-2.
Additionally, in concert with what would be expected from our mouse model, many of
the predicted up-regulated factors were related to inflammatory cytokines produced in
our model.

Hoxa9 and EBF-1 are down-regulated in CLPs exposed to CpG induced
inflammation.
We then interrogated transcriptional levels of Hoxa9 and some of its targets by
qRTPCR. We found that Ly-6D- CLPs from CpG treated mice had lower levels of
Hoxa9 than their PBS treated counterparts. Known Hoxa9 targets important for B cell
specification, Flt3, IL-7Rα and RAG1, (Gwin et al., 2013a; Gwin et al., 2010; Gwin et
al., 2013b; Izon et al., 1998) were also decreased (Figure 16A). As many of these targets
are also known to be mediated by the transcription factor E2A, we looked at E2A and its
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unique

target

FOXO1

but

found

that

neither

were

significantly

decreased

transcriptionally, suggesting that alterations in Hoxa9 may preferentially account for the
decreases in Flt3, RAG1, and IL-7Rα in CpG treated mice (Figure 16B). While E2A is
primarily regulated at the protein level, lack of change in FOXO1 suggests that it is not
decreased. EBF-1, a target of IL-7Rα and an important factor for initiating the B cell
program, (Tsapogas et al., 2011) was also decreased in Ly-6D- CLPs, (Figure 16A).
Together these data suggest that Hoxa9 and EBF-1 are decreased in CpG treated CLPs
and perhaps account for the skewing away from the B cell lineage.
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Chapter 5
Discussion

The complex inflammatory environment induced by sustained TLR9 activation
leads to distinct transcriptional programs in CLP populations. Via both a bioinformatics
approach and by examining transcript levels, we identified loss of Hoxa9 and its indirect
target EBF-1 as potential pathways by which inflammation suppresses B lymphopoiesis.
It is interesting to note that NFkB activation suppresses Hoxa9 transcription in a number
of different cell types, (Trivedi et al., 2008) consistent with a role for inflammation in this
process. While Hoxa9 is important for development of other lineages, Hoxa9 mutant
mice have more profound effects in the B cell pathway. (Lawrence et al., 1997) Since
EBF-1 is one of the orchestrating factors of the B cell program, its decrease could allow
for progenitors to remain open to other lineage fates although our data suggest this is
specific to the T cell and not dendritic cell fates. EBF-1 is normally expressed at high
levels during the Ly-6D+ stage of B cell differentiation, which may be why it did not
come out of the pathway analysis program, which was focused on Ly-6D- CLPs.
Our data surprisingly suggested that Ly-6D- CLPs exposed to the CpG induced
inflammatory environment are impaired in their ability to become B cells, enhanced to
become T cells, and indifferent to become DCs. This may be due to yet unknown
regulation of genes important for the T cell fate by CpG induced inflammation. In fact,
when we look at the raw values from the microarray, TCF1 transcripts are significantly
increased in both Ly-6D- and Ly-6D+ CLPs exposed to CpG induced inflammation (data
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not shown). This is surprising as Notch1 transcripts were significantly decreased in Ly6D- CpG CLPs (data not shown), and Notch induces TCF1 under homeostatic conditions.
This suggests that there may be factors biasing progenitors towards or against the T and
B cell fates that are yet unclear and that there is a connection between inflammation and
induction of TCF1. Perhaps inflammation serves to augment the low level of Notch
signaling present in the bone marrow. Previous studies have suggested that TLR9
signaling drives CLPs towards the dendritic cell fate. (Welner et al., 2008) However,
these studies examined bulk CLPs, and thus the loss of Ly-6D+ CLPs during
inflammation would skew the bulk CLP population towards the Ly-6D- CLPs that have
broader differentiation capabilities. This would make it appear as if bulk CLPs have
greater DC potential. In our report, we separate the Ly-6D- and Ly-6D+ populations
revealing their true B and DC potentials. This may be due to skewing of individual cells
away from the B cell fate or from further heterogeneity within the CLP compartment.
Consistent with our cell culture findings, levels of E2-2 are not significantly changed in
our array data (data not shown).
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Table I. Ingenuity Pathway Analysis of Ly-6D- CLPs from CpG and PBS treated
mice.

Upstream Regulator

p-value of overlap

HOXA9
POR
HOXA7
RB1
CD3

Activation
Z-score
-3.08
-2.813
-2.789
-2.262
-2.076

IFNγ
CD38
IL5
STAT3
IL6
IL1B
CSF2
IL4
IFN alpha/beta
Ifnar
IKBKB
APP

3.857
3.536
3.019
2.954
2.691
2.673
2.670
2.638
2.191
2.135
2.122
2.087

3.71e-07
3.67e-07
5.71e-07
2.74e-05
1.82e-08
1.56e-04
4.23e-05
1.84e-08
3.84e-05
3.79e-04
1.74e-05
1.72e-05

5.45e-06
1.65e-04
1.49e-07
3.17e-04
8.76e-06
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Chapter 6
Future Directions and Discussion

Apoptosis versus proliferation
While it is known that inflammation alters hematopoiesis, it is unclear if
individual factors act on the progenitors or on the environment and whether they act at
multiple stages. In this thesis, we have shown that B and T lymphopoiesis are diminished
in a cell intrinsic manner by both TLR9 and IFN-γR signaling, and that they act
independently at multiple stages of development. TLR9 skews early progenitors away
from the B cell fate towards the T cell as well as decreases Pre B cell numbers in vitro.
IFN-γ acts independently of CpG, directly decreasing both T and B cells likely at
multiple stages of development. While CpG does affect lineage determination, it is still
unclear whether TLR9 and IFN-γR signaling induce apoptosis or reduce proliferation of
developing cells. In another mouse model, high dose CpG stimulation inhibits Pro B cell
proliferation by inducing apoptosis. (Lalanne et al., 2010) Preliminary data from our lab
found similar rates of apoptotic B cell progenitors by annexin V staining (data not
shown). While this could be because apoptosis is not a primary factor leading to
decreased lymphopoiesis, it is also possible that apoptotic cells are cleared too quickly in
vivo and therefore changes in rates are undetectable. Future work employing other
methods to detect apoptosis including TUNEL staining for DNA fragmentation may be
useful in vivo and in in vitro co-cultures. Additionally, if the main cause of decreased
lymphopoiesis is due to apoptosis, blocking apoptosis should allow cells to overcome this
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defect. Use of B cell lymphoma (BCL)-xL or BCL-2 transgenic mice the transgene under
control of lymphoid restricted promoters should shed light on whether apoptosis is a main
contributor. Proliferation can be tested in vitro by labeling CLPs with carboxyfluorescein
succinimidyl ester (CFSE) before plating them on OP9 cells. Dilution of CFSE based on
the number of cell divisions can then be compared between CpG and PBS conditions.
This method will require optimization as we attempted this once with in vitro CpG
administration but had poor survival of CLPs after CFSE labeling. Analysis of the few
surviving cells showed full CFSE dilution between both CpG and PBS treated samples
suggesting that the surviving cells have normal proliferative capacities (data not shown).
Feeding mice bromodeoxyuridine (BrdU), a synthetic nucleoside analog of thymidine
that is incorporated into proliferating cells, would allow for detection of proliferating
cells in vivo. Like CFSE, Brdu levels would dilute out every time the cells proliferate
and can be assayed by flow cytometry using antibodies against BrdU. If CLPs, Pro, and
Pre B cells have reduced levels of proliferation in CpG treated mice, one would expect to
see fewer rounds of BrdU dilution. Single cell or liming dilution assays could be used to
asses changes in cell intrinsic capabilities to become B versus T cells with CpG
administration in vitro. We attempted these studies but had poor survival of CLPs at
lower concentrations. Therefore these methods will require further optimization.

Decreased thymic cellularity
How inflammatory factors mediate the decrease in thymopoiesis in our model is
unclear. While we see decreased levels of CCR9 on Ly-6D- CLPs from CpG treated
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mice, a homing defect would not fully account for decreases in thymic subsets across
development. Homing defects have minimal effects on thymic cellularity, but profound
effects on early thymic progenitor numbers. (Zlotoff et al., 2010) Therefore, the primary
contributor to the decrease in total thymic cellularity is likely due to an effect of the
inflammation on the thymus itself. Recent work looking at the effects of irradiation on
thymic development has shown that irradiation leads to decreased thymic epithelial cell
numbers. These thymic epithelial cells are important for producing the chemokines that
recruit thymic settling progenitors and provide the space required for T cell development.
Decreased epithelial cells would then lead to decreased homing in addition to downsizing
the thymic niche so it cannot support normal levels of thymopoiesis. (Zhang et al., 2014b;
Zlotoff et al., 2011) Decreased epithelial cells could account for the decreased thymocyte
numbers across all stages of thymopoiesis seen in our model. Future studies
characterizing the number and transcriptional profiles of thymic epithelial cells during
inflammation may be useful in determining how thymic cellularity is decreasing and
whether epithelial cell production of thymic growth factors are altered.

Roles of EBF-1 and Hoxa9 in mediating decreased B lymphopoiesis
Our work identified the important B cell lineage factors EBF-1 and Hoxa9 as
being decreased in early progenitors from CpG treated mice. It is unclear which
inflammatory factors directly mediate the decreases in Hoxa9 and EBF-1. Because TLR9
signaling had similar effects in vitro, we sorted CLPs from treated TLR9 mixed bone
marrow chimeras with the intention of looking at EBF-1 and Hoxa9 levels. If TLR9
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signaling directly leads to these decreases, then only the TLR9 sufficient CLPs in the
CpG treated mice would have defects in expression. Unfortunately, we are yet unable to
perform transcriptional analysis due to recovery of low numbers of CLPs. To assess
whether EBF-1 and Hoxa9 can rescue defects in B lymphopoiesis, future studies
transfecting bone marrow with EBF-1 or Hoxa9 expressing constructs would be useful.
These cells could then be used in vitro or to make bone marrow chimeras to assess
whether forced expression of EBF-1 or HOXa9 restore B lymphopoiesis. EBF-1 turns on
early in B cell commitment and stays on throughout development. It specifies the B cell
fate, which may rescue defects associated with potential TLR9 skewing of early
progenitors away from the B cell lineage. Additionally, as EBF-1 interacts with IL-7, it is
possible that restoration of EBF-1 levels could improve survival and differentiation of B
cells and mitigate the effects of inflammation. Control of Hoxa9 expression during
development is more nuanced, with its peak expression occurring during the Ly-6D- stage
before turning back off. In fact, over-expression of Hoxa9 leads to suppression of B
lymphopoiesis. (Thorsteinsdottir et al., 2002) Forced expression of Hoxa9 in CpG and
PBS treated mice would be difficult but may still be useful when comparing numbers of
Ly-6D+ CLPs and Pro B cells.

Discussion
A multitude of potential factors can induce hyperinflammation leading to
alterations in hematopoiesis. Depending on the instigating signals and dominating
cytokines, the resulting inflammation can lead to mobilization of precursors, increased or
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decreased myelo- or lymphopoiesis, and skewing of progenitors towards different
populations. While it is known that certain cytokines such as TNFα and IL-1 impact
lymphopoiesis, our work provides novel insights into how TLR9 driven cytokine storm
and IFN-γ are acting directly on hematopoietic progenitors at multiple stages of
development to impair lymphopoiesis. Sustained TLR9 mediated inflammation occurs in
a number of clinical scenarios such as viral or bacterial sepsis and auto-inflammatory
disorders including lupus or rheumatoid arthritis. Immuno-paralysis in sepsis, and B cell
autoimmunity in lupus may in part arise from dysfunctional B lymphopoiesis. Other
hyperinflammatory scenarios where IFN-γ is a dominant inflammatory cytokine, such as
HLH, are associated with B and T lymphopenias and suppression of genes important for
B lymphopoiesis. (Hinze et al., 2010; Sumegi et al., 2011) As the effects of TLRs and
inflammatory cytokines signaling on hematopoiesis are better understood, specific
blocking agents may serve as effective therapeutics to improve bone marrow homeostasis
in patients during hyperinflammation.
It is interesting to speculate why lymphopoiesis is suppressed during
inflammation.

Emergency myelopoiesis at the expense of lymphopoiesis is well

described. (Behrens et al., 2011) Mice over-expressing TLR7 develop a lupus-like
syndrome with high levels of type 1 interferons and increased myelopoiesis in the bone
marrow and periphery. (Buechler et al., 2013) LPS stimulation of TLR4 causes increased
myelopoiesis in a stromal cell dependent manner due to high production of granulocyte
colony-stimulating factor. (Boettcher et al., 2012; Quinton et al., 2002) However, our
data does not provide evidence of increased bone marrow myelopoiesis. Since we see
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decreased lymphopoiesis without an increase in myeloid or dendritic cell development, it
suggests that these are not simply reciprocal functions, but that each is driven by separate
factors. This is supported by data from other models that show TNFα induces migration
of B lymphoid progenitors from the marrow whereas IL-1 is required for increased
myelopoiesis. (Cain et al., 2011; Ueda et al., 2005; Ueda et al., 2004) Further
characterization of myeloid precursors in the marrow and periphery may shed light on
whether CpG induced inflammation affects myelopoiesis.
If reduced lymphopoiesis is not due to skewing of progenitors towards myeloid
cell fates, an alternative hypothesis is that shutting down lymphopoiesis is the immune
system’s attempt to prevent development of autoreactive B and T cells. This may
especially be relevant with DNA based TLR9 stimulation that leads to nuclear antigen
reactive B cells. In fact, lupus patients with anti-nuclear antibodies have higher
percentages of peripheral blood mononuclear cells that express TLR9. TLR9 expression
also correlates with disease severity. (Klonowska-Szymczyk et al., 2014) TLR9 is
important for development of anti-DNA antibodies in mice. (Christensen et al., 2005)
MRL/MPlpr/lpr mice, which are predisposed to developing a lupus-like syndrome due to a
mutation in Fas, produce significantly less anti-DNA and anti-chromatin antibodies when
crossed to TLR9 mutant mice. (Christensen et al., 2005) Similar effects are observed in
lupus mice crossed to TLR7 deficient mice, which develop significantly fewer anti-RNA
antibodies and produce less type 1 interferons. (Jackson et al., 2014) The role of TLR7
and TLR9 in promoting development of anti-nucleotide antibodies was found to be B cell
and not myeloid cells intrinsic expression of TLR7 as conditional TLR knockouts in B
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cells replicated the findings of straight knockouts crossed to the lupus MRL/MPlpr/lpr
background. (Jackson et al., 2014) This suggests that preventing B lymphopoiesis during
TLR stimulation causes the developing population to be skewed away from DNA
reactive B cells. Long-term experiments monitoring for development of auto-immunity or
auto-inflammation after exposure to hyperinflammation while open ended, may shed
light on the consequences of decreased lymphopoiesis during inflammation. Studies
testing T and B cell repertoires after inflammation may also prove useful in
understanding whether decreased lymphopoiesis, or prevention by using TLR9 or IFN-γ
blocking antibodies, alters the repertoires and skews developing cells towards known
heavy chain usages associated with higher rates of autoimmunity.
Because of DNA’s immuno-stimulatory role, CpG is considered a vaccine
adjuvant. However, its use has yielded mixed results, potentially because of its inhibitory
roles in lymphopoiesis. Our work suggests that repeated dosing of CpG leads to abnormal
lymphopoiesis, which may alter the immuno-repertoire.

Sustained decreased in

lymphopoiesis may compromise the immune system thereby potentially supporting tumor
growth or infection. In a human phase 1 study using TLR9 agonism to activate cells
against cutaneous T cell lymphoma, 54% of patients exhibited lymphopenias. (Kim et al.,
2010) Response rates varied depending on the dose of TL9 agonist given with no clear
correlation between dose and clinical response. In another phase 1 study of CpG as an
adjuvant for a tumor specific peptide, human telomerase reverse transcriptase, patients
developed lymphopenia with very low circulating B, NK, and T cell numbers. (Haining et
al., 2008) Clinical responses in this trial were also varied with few patients exhibiting
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clear responses to treatment. As mature B cells are tolerant of self-antigens, impaired
lymphopoiesis due to adjuvant induced inflammation could compromise generation of
new B cells reactive against the tumor peptide. CpG may act as an appropriate adjuvant
for certain cancers and infections, yet its actions on lymphopoiesis and ability to induce
auto-reactive B cells may undermine its effectiveness compared to other adjuvants
currently in use.
CpG treatment is effective in mediating B cell acute lymphoblastic leukemia (BALL) in mouse models. Mice injected with syngeneic B-ALL cells normally die within
40 days due to tumor burden. However, mice given repeated CpG doses 7 days after
tumor injection are able to clear the tumor and have near 100% survival at 140 days.
(Fujii et al., 2007; Seif et al., 2009) This increased survival is in part due to CpG acting
on innate and lymphoid cells as mice lacking certain arms of the innate immune system
impaired tumor clearance. (Fujii et al., 2007; Seif et al., 2009) One hypothesis is that
CpG is acting as an adjuvant for tumor peptides, however, it is also possible that the
inflammation induced by repeated CpG injections, including type 1 and 2 interferons
contribute to inhibiting B-ALL growth.
Not all hyperinflammation is equal. Depending on the cytokines that control the
inflammatory network, the resulting pathologies can lead to excess stimulation of certain
arms of the immune system. In particular, certain cytokines decrease hematopoiesis of
various lineages while some increase production of other lineages or lead to mobilization
of hematopoiesis from the bone marrow. Prior to the work within this thesis, the roles of
TLR9 and IFN-γR signaling on lymphopoiesis were unclear. We have shown that
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hyperinflammation downstream of TLR9 stimulation impairs B and T lymphopoiesis at
multiple stages of development in part via distinct IFN-γR and TLR9 pathways. TLR9
acts at the CLP stages skewing progenitors away from the B cell lineage. In contrast IFNγ acts on both T and B cell fates diminishing lymphopoiesis. Additionally, our data
suggest that CLPs exposed to the in vivo inflammatory environment have diminished
capability to differentiate into B cells even when removed from the inflammation, This is
possibly due to reduced levels of transcription factors important for B cell development.
These CLPs are skewed towards the T cell lineage rather than the DC lineage, which
suggests that the DC lineage is more disparate from the B cell lineage compared to the T
cell lineage. Together our findings provide insights into the mechanisms that allow
inflammation and hypercytokinemia to inhibit B and T cell development. As specific
cytokine blocking therapeutics continue to have expanded clinical applications, an
enhanced understanding of how cytokines regulate B cell development in disease will be
important for predicting efficacy and toxicity of these agents.
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Appendix
Abbreviations

B
B220, protein tyrosine phosphatase receptor type c
B-ALL, B cell acute lymphoblastic leukemia
BCL, B cell lymphoma
BCR, B cell receptor

C
CD, cluster of differentiation
cDC, conventional dendritic cell
CFSE, carboxyfluorescein succinimidyl ester
cKit, stem cell growth factor receptor
CLP, common lymphoid progenitor
CXCL, C-X-C motif chemokine ligand

D
DC, dendritic cell
Dl1, delta-like 1
DN, double negative
DNA, deoxyribonucleic acid
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DP, double positive

E
E2A, transcription factor 3
EBF-1, early B cell factor 1
ETP, early thymic progenitor

F
Flt3, fms related tyrosine kinase 3
Flt3l, fms related tyrosine kinase 3 ligand

H
HLH, hemophagocytic lymphohistiocytosis
HOXa9, homeobox A9

I
Id2, inhibitor of DNA binding 2
IFN, interferon
IFNα-R, interferon-alpha receptor
IFN γ -R, interferon-gamma receptor
Ig, immunoglobulin
IL-7Rα, Interleukin 7 receptor alpha
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IPA, ingenuity pathway analysis

L
LMPP, lymphoid primed multipotent progenitor
Ly-6D, lymphocyte antigen 6 complex, locus D

M
MHC, major histocompatibility complex

N
NK, natural killer

P
PAX5, paired box gene 5
PBS, phosphate buffered saline
pDC, plasmacytoid dendritic cell
Pu-1, spleen focus forming virus pro-viral integration oncogene

Q
qRTPCR, quantitative real-time polymerase chain reaction
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R
RAG, recombination activating gene
RNA, ribonucleic acid

S
Sca-1, lymphocyte antigen 6 complex, locus A/E
SCF, stem cell factor

T
TCF1, T cell factor-1
TCR, T cell receptor
TLR, toll-like receptor
TNF, tumor necrosis factor

W
WT, wild type
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